Search
BAX 335
go.drugbank.com/drugs/DB17845InvestigationalBAX 335 is an adeno-associated virus vector 8 (AAV8)–based FIX gene therapy being investigated for the treatment of hemophilia B.[A259791]
TRK-001
go.drugbank.com/drugs/DB18577InvestigationalIt is being investigated for the prevention of graft rejection following solid organ transplantation.
Dithiopyr
go.drugbank.com/drugs/DB15230InvestigationalDithiopyr is under investigation in clinical trial NCT01236781 (Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates).
Relamorelin
go.drugbank.com/drugs/DB12678InvestigationalRelamorelin has been investigated for the treatment and basic science of Gastroparesis, Gastric Motility, Diabetes Mellitus, Parkinson's Disease, and Chronic Constipation, among others.
Dextranomer
go.drugbank.com/drugs/DB13560InvestigationalCategories: Preparations for Treatment of Wounds and Ulcers, Compounds used in a research, industrial, or household settingLoprazolam
go.drugbank.com/drugs/DB13643ExperimentalIt is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or frequent nocturnal awakenings.
Smilagenin
go.drugbank.com/drugs/DB05450InvestigationalP58 therefore provides a totally novel mode of action with potential importance for diseases associated with ageing of the brain. … P58 is one of a family of phytochemicals isolated from traditional treatments for the elderly that have previously been shown to offer significant benefit in the treatment of senile dementia.
Efprezimod alfa
go.drugbank.com/drugs/DB16448InvestigationalCD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
Categories: Experimental Unapproved Treatments for COVID-19Sarconeos
go.drugbank.com/drugs/DB16457InvestigationalSarconeos is an activator of the MAS receptor.
Categories: Experimental Unapproved Treatments for COVID-19Empasiprubart
go.drugbank.com/drugs/DB16469InvestigationalEmpasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.
Categories: Experimental Unapproved Treatments for COVID-19